‘The serial painkiller’: this is how the Financial Times (27 oct. 2011, see here) describes the history of aspirin, the well-known medicine invented more than a century ago, when Bayer’s chemist Felix Hoffmann synthetized a stable form of its active ingredient. Aspirin is undissociable from Bayer, but the benefits of its active ingredient were apparently […]
Tag Archives | Pharma
Bayer’s aspirin: a lasting success without patent and strong trademark protection
By 28 October 2011 0
Challenging pharmaceutical patents : a « death spiral » for generic companies ?
By 3 October 2010 0
I remain puzzled by an article in the Financial Times (1 Oct. 2010) which highlights recent doubts of the US generic pharmaceutical industry with regard to the strategy of challenging drug patents in the courts. The article quotes Mr Paul Bisaro, president of Watson Pharmaceuticals (one of the US’s largest generic drug companies) and head […]
‘Pay for delay’ deals in the pharmaceutical industry
By 1 October 2010 30
(Edited version, October 11, 2013) ‘Pay for delay’ deals are commonplace in the pharmaceutical industry; they involve branded drug makers paying generic groups to delay the launch of lower-cost versions of their drugs. Last July, the US House of Representatives passed a legislation banning such deals. These deals are also at the center of European […]
Half-day conference on the commission’s pharmaceutical sector requiry
By 1 September 2010
Documents Programme The EC Commission’s Sector Inquiry – Start, Provess and Provisional Findings by Philipp GASPARON Patent Litigation, Disputes and Settlements between Originators and Generic Companies by David HULL Regulatory Issues behind the Sector Inquiry by James KILLICK Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry by Elke […]